Pronóstico del mercado de servicios de farmacocinética en Europa hasta 2031: análisis regional, por tipo de fármaco (moléculas pequeñas, moléculas grandes y vacunas), tipo de servicio (estudios preclínicos de ADME y humanos, análisis y generación de informes de PK/PD, simulaciones de dosificación, análisis de riesgos y otros), aplicación terapéutica (oncología, enfermedades infecciosas, trastornos neurológicos, enfermedades autoinmunes, trastornos ginecológicos, enfermedades cardiovasculares, trastornos respiratorios y otros) y usuario final (empresas farmacéuticas y de biotecnología, organizaciones de investigación por contrato y otros)

BMIRE00030902 | Pages: 87 | Pharmaceuticals | Oct 2024 | Type: Regional | Status: Published

El mercado europeo de servicios farmacocinéticos se valoró en 222,16 millones de dólares en 2023 y se espera que alcance los 387,38 millones de dólares en 2031; se estima que registrará una CAGR del 7,2% entre 2023 y 2031.

La subcontratación de servicios farmacocinéticos a organizaciones de investigación por contrato (CRO) impulsa el mercado europeo de servicios farmacocinéticos

La subcontratación de servicios farmacocinéticos a organizaciones de investigación por contrato (CRO) ofrece varias ventajas a los fabricantes y patrocinadores de medicamentos. Pueden operar de forma rentable al optar por estos servicios. Además, pueden centrarse en trabajar de forma flexible y aportar escalabilidad a sus operaciones principales, además de lograr un tiempo de respuesta rápido. La subcontratación ayuda a las empresas farmacéuticas a centrarse en la comercialización de productos al tiempo que implementan medidas para el desarrollo de capacidades, la reducción de costes y la gestión de datos. El proceso de descubrimiento de fármacos es complejo y cualquier error o resultado falso puede suponer costes significativos y retrasar el proceso. Las CRO emplean a científicos e investigadores experimentados que tienen experiencia en farmacocinética y otros campos. De esta manera, brindan a las compañías farmacéuticas acceso a su experiencia, eliminando así la necesidad de invertir en la contratación de mano de obra calificada o en brindar capacitación adicional para desarrollarla. Por lo tanto, las pequeñas empresas con candidatos a medicamentos prometedores pero recursos limitados y las grandes empresas involucradas en la diversificación de sus operaciones están optando por servicios de investigación clínica proporcionados por CRO bien organizadas, lo que refuerza el mercado de servicios farmacocinéticos de Europa.

Resumen del mercado de servicios farmacocinéticos de Europa

El mercado de servicios farmacocinéticos de Europa está segmentado en Alemania, Francia, el Reino Unido, España, Italia y el resto de Europa. Se espera que países como Alemania e Italia representen una participación significativa en el mercado de la región, y es probable que países como Francia, el Reino Unido y España tengan oportunidades de crecimiento para los servicios farmacocinéticos. Se espera que el mercado europeo de servicios farmacocinéticos crezca en los próximos años con el creciente número de ensayos clínicos para el desarrollo de nuevos medicamentos y la creciente adopción de modelos in vivo e in vitro para comprender la variabilidad farmacocinética.

Ingresos y pronóstico del mercado de servicios farmacocinéticos en Europa hasta 2031 (millones de USD)

Segmentación del mercado de servicios farmacocinéticos en Europa

El mercado de servicios farmacocinéticos en Europa se clasifica en tipo de fármaco, tipo de servicio, aplicación terapéutica, usuario final y país.

Según el tipo de fármaco, el mercado de servicios farmacocinéticos en Europa se segmenta en moléculas pequeñas, moléculas grandes y vacunas. El segmento de moléculas pequeñas tuvo la mayor participación de mercado en 2023.

En términos de tipo de servicio, el mercado de servicios farmacocinéticos en Europa se clasifica en estudios preclínicos ADME y humanos, análisis y generación de informes PK/PD, simulaciones de dosificación, análisis de riesgos y otros. El segmento de estudios preclínicos en humanos y ADME tuvo la mayor participación de mercado en 2023.

Por aplicación terapéutica, el mercado de servicios farmacocinéticos de Europa está segmentado en oncología, enfermedades infecciosas, trastornos neurológicos, enfermedades autoinmunes, trastornos ginecológicos, enfermedades cardiovasculares, trastornos respiratorios y otros. El segmento de oncología tuvo la mayor participación de mercado en 2023.

Por usuario final, el mercado de servicios farmacocinéticos de Europa está segmentado en empresas farmacéuticas y biotecnológicas, organizaciones de investigación por contrato y otros. El segmento de organizaciones de investigación por contrato tuvo la mayor participación de mercado en 2023.

Por país, el mercado de servicios farmacocinéticos de Europa está segmentado en Alemania, Francia, Reino Unido, Italia, España y el resto de Europa. Francia dominó la participación de mercado de servicios farmacocinéticos de Europa en 2023.

Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; y SGS SA son algunas de las empresas líderes que operan en el mercado de servicios farmacocinéticos de Europa.

TABLE OF CONTENTS

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Europe Pharmacokinetics Services Market - Key Market Dynamics

4.1 Market Drivers

4.1.1 Rising Prevalence of Chronic and Infectious Diseases

4.1.2 Expanding Range of Application of Pharmacokinetic Studies

4.1.3 Outsourcing of Pharmacokinetics Services to CROs

4.2 Market Restraints

4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries

4.3 Market Opportunities

4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics

4.4 Future Trend

4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services

4.5 Impact of Drivers and Restraints:

5. Pharmacokinetics Services Market - Europe Analysis

5.1 Europe Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

6. Europe Pharmacokinetics Services Market Analysis - by Drug Type

6.1 Overview

6.2 Small Molecule

6.2.1 Overview

6.2.2 Small Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

6.3 Large Molecule

6.3.1 Overview

6.3.2 Large Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

6.4 Vaccines

6.4.1 Overview

6.4.2 Vaccines: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7. Europe Pharmacokinetics Services Market Analysis - by Service Type

7.1 Overview

7.2 Pre-Clinical ADME and Human Studies

7.2.1 Overview

7.2.2 Pre-Clinical ADME and Human Studies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7.3 PK/PD Analysis and Reporting

7.3.1 Overview

7.3.2 PK/PD Analysis and Reporting: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7.4 Dosing Simulations

7.4.1 Overview

7.4.2 Dosing Simulations: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7.5 Risk Analysis

7.5.1 Overview

7.5.2 Risk Analysis: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7.6 Others

7.6.1 Overview

7.6.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Pharmacokinetics Services Market Analysis - by Therapeutic Application

8.1 Oncology

8.1.1 Overview

8.1.2 Oncology: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.2 Infectious Diseases

8.2.1 Overview

8.2.2 Infectious Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.3 Neurological Disorders

8.3.1 Overview

8.3.2 Neurological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.4 Autoimmune Diseases

8.4.1 Overview

8.4.2 Autoimmune Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.5 Gynecological Disorders

8.5.1 Overview

8.5.2 Gynecological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.6 Cardiovascular Diseases

8.6.1 Overview

8.6.2 Cardiovascular Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.7 Respiratory Disorders

8.7.1 Overview

8.7.2 Respiratory Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.8 Others

8.8.1 Overview

8.8.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Pharmacokinetics Services Market Analysis - by End User

9.1 Pharmaceutical and Biotechnology Companies

9.1.1 Overview

9.1.2 Pharmaceutical and Biotechnology Companies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9.2 Contract Research Organization

9.2.1 Overview

9.2.2 Contract Research Organization: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9.3 Others

9.3.1 Overview

9.3.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. Europe Pharmacokinetics Services Market - Country Analysis

10.1 Europe

10.1.1 Europe Pharmacokinetics Services Market Breakdown by Countries, 2023 and 2031 (%)

10.1.1.1 Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.1.1 Overview

10.1.1.1.2 Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.1.3 Germany: Europe Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.1.4 Germany: Europe Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.1.5 Germany: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.1.6 Germany: Europe Pharmacokinetics Services Market Breakdown, by End User

10.1.1.2 France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.2.1 Overview

10.1.1.2.2 France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.2.3 France: Europe Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.2.4 France: Europe Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.2.5 France: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.2.6 France: Europe Pharmacokinetics Services Market Breakdown, by End User

10.1.1.3 United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.3.1 Overview

10.1.1.3.2 United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.3.3 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.3.4 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.3.5 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.3.6 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by End User

10.1.1.4 Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.4.1 Overview

10.1.1.4.2 Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.4.3 Italy: Europe Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.4.4 Italy: Europe Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.4.5 Italy: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.4.6 Italy: Europe Pharmacokinetics Services Market Breakdown, by End User

10.1.1.5 Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.5.1 Overview

10.1.1.5.2 Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.5.3 Spain: Europe Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.5.4 Spain: Europe Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.5.5 Spain: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.5.6 Spain: Europe Pharmacokinetics Services Market Breakdown, by End User

10.1.1.6 Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.6.1 Overview

10.1.1.6.2 Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.6.3 Rest of Europe Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.6.4 Rest of Europe Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.6.5 Rest of Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.6.6 Rest of Europe Pharmacokinetics Services Market Breakdown, by End User

11. Company Profile

11.1 Charles River Laboratories International Inc

11.1.1 Key Facts

11.1.2 Business Description

11.1.3 Products and Services

11.1.4 Financial Overview

11.1.5 SWOT Analysis

11.1.6 Key Developments

11.2 Eurofins Scientific SE

11.2.1 Key Facts

11.2.2 Business Description

11.2.3 Products and Services

11.2.4 Financial Overview

11.2.5 SWOT Analysis

11.2.6 Key Developments

11.3 Evotec SE

11.3.1 Key Facts

11.3.2 Business Description

11.3.3 Products and Services

11.3.4 Financial Overview

11.3.5 SWOT Analysis

11.3.6 Key Developments

11.4 Certara Inc.

11.4.1 Key Facts

11.4.2 Business Description

11.4.3 Products and Services

11.4.4 Financial Overview

11.4.5 SWOT Analysis

11.5 Parexel International Corp

11.5.1 Key Facts

11.5.2 Business Description

11.5.3 Products and Services

11.5.4 Financial Overview

11.5.5 SWOT Analysis

11.5.6 Key Developments

11.6 Thermo Fisher Scientific Inc.

11.6.1 Key Facts

11.6.2 Business Description

11.6.3 Products and Services

11.6.4 Financial Overview

11.6.5 SWOT Analysis

11.6.6 Key Developments

11.7 Allucent

11.7.1 Key Facts

11.7.2 Business Description

11.7.3 Products and Services

11.7.4 Financial Overview

11.7.5 SWOT Analysis

11.7.6 Key Developments

11.8 PACIFIC BIOLABS

11.8.1 Key Facts

11.8.2 Business Description

11.8.3 Products and Services

11.8.4 Financial Overview

11.8.5 SWOT Analysis

11.8.6 Key Developments

11.9 SGS SA

11.9.1 Key Facts

11.9.2 Business Description

11.9.3 Products and Services

11.9.4 Financial Overview

11.9.5 SWOT Analysis

11.9.6 Key Developments

12. Appendix

12.1 About The Insight Partners

12.2 Glossary of Terms for Pharmacokinetic Services Market

 

?

List of Tables

Table 1. Europe Pharmacokinetics Services Market Segmentation

Table 2. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 3. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 4. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 5. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 6. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 7. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 8. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 9. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 10. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 11. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 12. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 13. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 14. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 15. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 16. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 17. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 18. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 19. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 20. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 21. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 22. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 23. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 24. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 25. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 26. Glossary of Terms

 

?

List of Figures

Figure 1. Europe Pharmacokinetics Services Market Segmentation, by Country

Figure 2. Europe Pharmacokinetics Services Market - Key Market Dynamics

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. Europe Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

Figure 5. Europe Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)

Figure 6. Small Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 7. Large Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 8. Vaccines: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 9. Europe Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)

Figure 10. Pre-Clinical ADME and Human Studies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 11. PK/PD Analysis and Reporting: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 12. Dosing Simulations: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 13. Risk Analysis: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 14. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 15. Europe Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)

Figure 16. Oncology: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 17. Infectious Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 18. Neurological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 19. Autoimmune Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 20. Gynecological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 21. Cardiovascular Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 22. Respiratory Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 23. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 24. Europe Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)

Figure 25. Pharmaceutical and Biotechnology Companies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 26. Contract Research Organization: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 27. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 28. Europe Pharmacokinetics Services Market - Revenue by Key Countries Revenue 2023 (US$ Million)

Figure 29. Europe Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)

Figure 30. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 31. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 32. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 33. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 34. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 35. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

  1. Allucent
  2. Certara Inc.
  3. Charles River Laboratories International Inc
  4. Eurofins Scientific SE
  5. Evotec SE
  6. PACIFIC BIOLABS
  7. Parexel International Corp
  8. SGS SA
  9. Thermo Fisher Scientific Inc.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe pharmacokinetics services market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Europe pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe pharmacokinetics services market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2485
Site License
$4550
$3185
Enterprise License
$5550
$3885